{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:05:11Z","timestamp":1781816711156,"version":"3.54.5"},"reference-count":31,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Aims<\/jats:title><jats:p>Alcohol use disorder (AUD) is a persistent public health concern, contributing significantly to mortality and morbidity. This study aims to evaluate the impact of in\u2010hospital extended\u2010release naltrexone (XR\u2010NTX) administration on alcohol\u2010related outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort study, conducted at an academic medical centre, included 141 adult patients with AUD who received XR\u2010NTX between December 2020 and June 2021. Primary and secondary outcomes were assessed 90\u2009days before and after XR\u2010NTX administration to identify number of alcohol\u2010related hospitalisations, emergency department (ED) visits and average length of hospital stay. Subgroup analyses assessed outcomes in high hospital utilisers and marginally housed or unhoused populations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There was a significant decrease in ED visits and length of hospital stay post XR\u2010NTX and no significant difference in the number of rehospitalisations. Subgroup analysis showed significant reduction in hospital readmissions and ED visits among high hospital utilisers. Our sample was a predominantly middle\u2010aged, male and white patient population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In\u2010hospital initiation of XR\u2010NTX for AUD was associated with a significant decrease in ED visits and length of hospital stay. While no significant impact on the number of hospitalisations was observed overall, there was a substantial reduction in hospital readmissions and ED visits among high utilisers. Our findings suggest the potential benefits of in\u2010hospital XR\u2010NTX, emphasising the need for further research to establish causal relationships, assess cost\u2010effectiveness and explore effectiveness across diverse patient populations. Effective in\u2010hospital interventions, such as XR\u2010NTX, hold promise for improving patient outcomes and reducing the healthcare burden associated with AUD.<\/jats:p><\/jats:sec>","DOI":"10.1111\/imj.16467","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T08:50:14Z","timestamp":1720601414000},"page":"1644-1651","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of hospital\u2010administered extended\u2010release naltrexone on readmission rates for patients with alcohol use disorder"],"prefix":"10.1111","volume":"54","author":[{"given":"Nathaniel M.","family":"Singh","sequence":"first","affiliation":[{"name":"College of Medicine University of Nebraska Medical Center  Omaha Nebraska USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Daniel","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical and Nutrition Care Nebraska Medicine, Nebraska Medical Center  Omaha Nebraska USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9735-2712","authenticated-orcid":false,"given":"Al\u0451na A.","family":"Balasanova","sequence":"additional","affiliation":[{"name":"Department of Psychiatry University of Nebraska Medical Center  Omaha Nebraska USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7,10]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association(Ed.).Diagnostic and Statistical Manual of Mental Disorders: DSM\u20105\u2010TR (Fifth edition text revision). American Psychiatric Association Publishing; 2022.","DOI":"10.1176\/appi.books.9780890425787"},{"key":"e_1_2_7_3_1","unstructured":"CDC.Alcohol and Public Health: Alcohol\u2010Related Disease Impact [Table]. Annual Average for United States 2015\u20132019 Alcohol\u2010Attributable Deaths Due to Excessive Alcohol Use All Ages. Available from URL:https:\/\/nccd.cdc.gov\/DPH_ARDI\/default\/default.aspx."},{"key":"e_1_2_7_4_1","unstructured":"Substance Abuse and Mental Health Services Administration. (2021).Key Substance Use and Mental Health Indicators in the United States: Results from the 2020 National Survey on Drug Use and Health (HHS Publication No. PEP21\u201007\u201001\u2010003 NSDUH Series H\u201056). Rockville MD: Center for Behavioral Health Statistics and Quality Substance Abuse and Mental Health Services Administration. Retrieved from URL:https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt35325\/NSDUHFFRPDFWHTMLFiles2020\/2020NSDUHFFR1PDFW102121.pdf."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-019-05251-9"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-021-07357-5"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-023-08194-4"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.1750101"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.35946\/arcr.v41.1.07"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820110040006"},{"key":"e_1_2_7_11_1","unstructured":"SinghD SaadabadiA.Naltrexone [Updated 2023 May 30]. In: StatPearls [Internet]. Treasure Island FL: StatPearls Publishing; 2023. Available from URL:https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534811\/."},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3628"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.13.1617"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ALC.0000130804.08397.29"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2022.2073300"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15572"},{"key":"e_1_2_7_17_1","first-page":"S222","article-title":"Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence","volume":"17","author":"Baser O","year":"2011","journal-title":"Am J Manag Care"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18168884"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-018-0125-1"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-014-2968-9"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.12788\/jhm.2900"},{"key":"e_1_2_7_22_1","article-title":"A retrospective study of hospital recidivism among patients with alcohol use disorders treated with intramuscular naltrexone","volume":"11","author":"Espiridion ED","year":"2019","journal-title":"Cureus"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2017.05.106"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/acer.13410"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.22m03213"},{"key":"e_1_2_7_26_1","unstructured":"Un H.Utilization and persistence with alcohol dependence pharmacotherapies in a large commercial insurance population. In SAMHSA\/CSAT Invitational Conference on Economic Access to Treatment Washington DC; 2008."},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3015(10)72509-2"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2017.11.005"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom11101495"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-022-07506-4"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.13455"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050225"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.16467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T15:28:49Z","timestamp":1727882929000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.16467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1111\/imj.16467"],"URL":"https:\/\/doi.org\/10.1111\/imj.16467","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,10]]},"assertion":[{"value":"2024-02-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}